Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study.
David Kavanagh, Andrew S Bomback, Marina Vivarelli...
https://pubmed.ncbi.nlm.nih.gov/41016405/Actively Recruiting
Led by Novartis Pharmaceuticals · Updated on 2026-07-13
98
Participants Needed
87
Research Sites
N/A
Total Duration
Researchers are evaluating the efficacy and safety of iptacopan compared to placebo and standard care in patients with native Complement 3 Glomerulopathy C3G. This Phase 3 pivotal trial aims to assess how iptacopan affects proteinuria levels, kidney function, and kidney tissue changes in both adult and adolescent participants. The study also examines improvements in serum C3 levels as a marker of treatment impact. Participants will be randomly assigned to receive either iptacopan 200 mg twice daily or a matching placebo. Treatment dosing differs slightly for adults and adolescents but follows a twice-daily schedule. The study includes a double-blind treatment period of 12 months, during which kidney biopsies will be performed in adults to evaluate tissue improvements. Vaccinations against certain bacteria are required prior to starting treatment. During the trial, participants will provide urine samples to measure protein levels and have kidney function assessed through estimated glomerular filtration rate eGFR. Safety evaluations include monitoring vital signs, ECGs, and laboratory tests. Fatigue levels will be assessed using a standardized questionnaire. Researchers will follow participants over 6 and 12 months to observe treatment effects and safety, with ongoing assessments during both double-blind and open-label phases.
CONDITIONS
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Novartis Pharmaceuticals
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Iptacopan (200 mg twice daily) | Placebo (matched schedule) |
|---|---|---|
| What it is | Oral iptacopan, a factor B inhibitor designed to modulate complement activation, administered as 200 mg twice daily for adults and 2 x 100 mg twice daily for adolescents. All participants continue standard background therapy. | Placebo, matched in schedule and appearance to iptacopan, given twice daily for adults and adolescents. All participants continue standard background therapy. |
| Role in trial | Evaluated for efficacy and safety in reducing proteinuria and improving renal outcomes in C3 glomerulopathy. | Serves as direct comparator for measuring efficacy and safety outcomes against iptacopan. |
| Primary use | Investigational treatment for C3 glomerulopathy, assessed for reduction in proteinuria and improvement in renal function. | Matched placebo to iptacopan, provides baseline for evaluating response to investigational treatment. |
| How it is given or performed | Oral tablets taken twice daily for adults; adolescents receive two 100 mg tablets twice daily. Dosing continues alongside background ACEI or ARB. | Placebo tablets given using the same twice daily schedule as iptacopan; background ACEI or ARB continued. |
| Evidence status | Phase 3 randomized trial evidence in APPEAR-C3G shows iptacopan significantly reduced proteinuria compared to placebo at 6 months; effect sustained through 12 months. Safety profile was consistent with previous findings. | Placebo arm provides comparison baseline; no active treatment effect observed. Outcomes reflect standard background therapy and trial-specific placebo control. |
| Important limitations | Results reflect participants with stable background therapy and specific eligibility. Long-term effects and real-world risks may differ from trial setting. Adverse events included mild to moderate infections; serious event risk remains under further follow-up. | Placebo arm did not provide active disease modification; reflects only background therapy as practiced in trial setting. Real-world management may use additional therapies outside protocol. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive either iptacopan or placebo taken twice daily as part of the study.
Regular visits for assessments and monitoring during treatment
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
David Kavanagh, Andrew S Bomback, Marina Vivarelli...
https://pubmed.ncbi.nlm.nih.gov/41016405/Novartis Pharmaceuticals
Lead Sponsor